According to BioSpace, Biohaven Pharma has utilized their MATE platform to create and develop a hyperimmune globulin mimic (HGM) that is able to both bind to and neutralize various strains of COVID-19. This breakthrough comes after accelerated development that has been supported by the Bill and Melinda Gates Foundation.
About the MATE Platform
This platform utilizes MATE conjugation technology, which targets and selectively conjugates COVID-19’s spike protein to immunoglobulin through the use of synthetic peptide binders. These binders are able to cover a larger area than previous methods, allowing them to make more contact with the spike protein.
While all focus is currently on the SARS-CoV-2 virus, this technology could potentially treat other infectious diseases. After it has been fully investigated for use during the pandemic, medical professionals can utilize this technology for other health crises.
Data on the MATE Platform
Research on this technology has demonstrated that it is able to both bind to and neutralize various forms of SARS-CoV-2, including the “English” (B.1.1.7) and “South African” (B.1.351) strain. This leads to lower viral entry into the cells, therefore reducing one’s chance of contracting the virus.
Further data taken from in vitro models found that the treatment may also activate antibody dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, both of which play an important role in the immune system.
Researchers are hopeful that further research leads to similar results, as we desperately need viable solutions and tools to fight COVID-19.